Aspira Pathlab & Diagnostics Ltd vs Torrent Pharmaceuticals Ltd
A side-by-side comparison of Aspira Pathlab & Diagnostics Ltd (ASPIRA) and Torrent Pharmaceuticals Ltd (TORNTPHARM) — valuation, profitability, growth, and financial health — to help you judge which is the stronger buy today.
On the numbers, Torrent Pharmaceuticals Ltd leads ASPIRA vs TORNTPHARM on 8 of 14 metrics (1 tied). See the breakdown below — the right pick still depends on your goals (value vs growth, risk appetite).
Valuation
How expensive each stock is relative to its earnings and book value. Lower usually means cheaper.
Profitability
How efficiently each company turns capital and sales into profit. Higher is better.
Growth
Three-year compounded growth. Faster-growing businesses can justify a higher valuation.
Size & financial health
Scale and balance-sheet strength. Bigger revenue/profit and lower debt are generally safer.
- + ["Company has reduced debt.", "Debtor days have improved from 42.1 to 25.3 days.", "Promoter holding has increased by 28.2% over last quarter."]
- − ["Stock is trading at 7.84 times its book value", "Though the company is reporting repeated profits, it is not paying out dividend", "Company has low interest coverage ratio.", "Company has a low return on equity of -2.31% over last 3 years.", "Company might be capitalizing the interest cost", "Earnings include an other income of Rs.0.52 Cr."]
- + ["Company has a good return on equity (ROE) track record: 3 Years ROE 26.2%", "Company has been maintaining a healthy dividend payout of 57.8%"]
- − ["Stock is trading at 19.2 times its book value", "The company has delivered a poor sales growth of 11.8% over past five years.", "Company might be capitalizing the interest cost"]
This comparison is for informational purposes only and is not investment advice. Please consult a SEBI-registered advisor before investing.